Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Upper Respiratory Drugs: Decongestants01:27

Upper Respiratory Drugs: Decongestants

Decongestants are a class of medications used primarily to alleviate nasal congestion, a common symptom resulting from allergies, colds, sinusitis, and other upper respiratory tract infections. These drugs work by activating α-adrenergic receptors, constricting small blood vessels in the nasal membranes. This action results in the opening of clogged nasal passages, thereby facilitating sinus drainage and relieving congestion.
Most decongestants are readily available over-the-counter in various...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: The Value of Tracheal Visualization in Tracheostomized Patients in Skilled and Long-Term Care Homes.

Cureus·2026
Same author

New Technique for Tramadol Dose Accuracy: Are Dosing Pumps the Solution?

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Homocystinuria in a consanguineous indigenous family from rural Honduras: a ten-year follow up and literature review of familial cases.

Archive of clinical cases·2026
Same author

Women Going Forward in Survival (Mujeres Avanzando a la Sobrevida): A Prospective Breast Cancer Cohort Study in Honduras.

JCO global oncology·2026
Same author

Congenital Knee Dislocation: A Case Report.

Clinical case reports·2026
Same author

Relevant pharmacokinetics, bioavailability, and bioequivalence studies on Chlorpheniramine maleate (various species): a review.

Frontiers in pharmacology·2025

Related Experiment Video

Updated: May 28, 2026

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
08:47

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Published on: March 3, 2023

Cardiac Safety of Intranasal Chlorpheniramine: An Exposure-Based Risk Assessment.

César Alas-Pineda1, Dennis J Pavón-Varela1, Kristhel Gaitán-Zambrano1

  • 1Moxie Health Group, Department of Research & Development, Hallandale Beach, FL 33009, USA.

Pharmaceuticals (Basel, Switzerland)
|May 27, 2026
PubMed
Summary
This summary is machine-generated.

Intranasal chlorpheniramine maleate (CPM) may offer better cardiac safety than oral CPM due to lower systemic exposure. However, limited clinical data necessitates further research to confirm this potential benefit for reducing arrhythmia risks.

Keywords:
QT prolongationcardiotoxicitychlorpheniraminedrug safetyhERGintranasal antihistaminespharmacokinetics

More Related Videos

Development of a Nose-only Inhalation Toxicity Test Chamber That Provides Four Exposure Concentrations of Nano-sized Particles
05:07

Development of a Nose-only Inhalation Toxicity Test Chamber That Provides Four Exposure Concentrations of Nano-sized Particles

Published on: March 18, 2019

Related Experiment Videos

Last Updated: May 28, 2026

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
08:47

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Published on: March 3, 2023

Development of a Nose-only Inhalation Toxicity Test Chamber That Provides Four Exposure Concentrations of Nano-sized Particles
05:07

Development of a Nose-only Inhalation Toxicity Test Chamber That Provides Four Exposure Concentrations of Nano-sized Particles

Published on: March 18, 2019

Area of Science:

  • Pharmacology and Toxicology
  • Cardiovascular Safety
  • Drug Delivery Systems

Background:

  • First-generation H1-antihistamines, like chlorpheniramine maleate (CPM), are linked to cardiac electrophysiological adverse effects, including QT interval prolongation and torsades de pointes (TdP).
  • These cardiac risks are exposure-dependent and associated with inhibition of cardiac ion channels.
  • Increased systemic exposure to CPM has been implicated in cardiac arrhythmias, prompting investigation into alternative administration routes.

Purpose of the Study:

  • To review mechanistic, preclinical, clinical, pharmacokinetic, and regulatory evidence on the cardiac safety of intranasal versus oral chlorpheniramine administration.
  • To assess whether intranasal administration of CPM could mitigate cardiac risks associated with systemic exposure.

Main Methods:

  • A narrative review integrating diverse evidence types: mechanistic, preclinical, clinical, pharmacokinetic, and regulatory.
  • Literature search conducted on PubMed, Google Scholar, and Scielo using keywords: cardiotoxicity, chlorpheniramine, QT prolongation, intranasal administration, and cardiac arrhythmias.
  • No language restrictions were applied to the literature search.

Main Results:

  • Dose-normalized pharmacokinetic analysis indicates comparable bioavailability between intranasal and oral CPM.
  • Intranasal administration uses lower doses (1.12-2.24 mg) compared to oral daily doses (4-12 mg/day), leading to reduced systemic exposure (Cmax and AUC).
  • Pharmacovigilance and epidemiological data specifically for intranasal CPM are lacking; dedicated safety trials are limited.

Conclusions:

  • Preclinical and in vitro studies suggest intranasal CPM administration may offer superior cardiac safety over the oral route.
  • Clinical data directly comparing the cardiac safety of intranasal versus systemic CPM in humans is extremely limited.
  • Further clinical trials, case-control studies, and regulatory database analyses are required to validate the theoretical cardiac safety benefits of intranasal CPM.